115 related articles for article (PubMed ID: 7641522)
1. Serum interleukin-6 level in patients with systemic sclerosis: lack of correlation with aminoterminal propeptide of type III procollagen.
Kucharz EJ; Jonderko G; Rubisz-Brzezinska J; Brzezinska-Wcisło L
Clin Rheumatol; 1995 May; 14(3):380-1. PubMed ID: 7641522
[No Abstract] [Full Text] [Related]
2. Plasma endothelin and the aminoterminal propeptide of type III procollagen (PIIINP) in systemic sclerosis.
Zachariae H; Heickendorff L; Bjerring P; Halkier-Sørensen L; Søndergaard K
Acta Derm Venereol; 1994 Sep; 74(5):368-70. PubMed ID: 7817674
[TBL] [Abstract][Full Text] [Related]
3. Serum aminoterminal propeptide of type III procollagen in progressive systemic sclerosis and localized scleroderma.
Zachariae H; Halkier-Sørensen L; Heickendorff L
Acta Derm Venereol; 1989; 69(1):66-70. PubMed ID: 2563612
[TBL] [Abstract][Full Text] [Related]
4. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
[TBL] [Abstract][Full Text] [Related]
5. Skin scoring in systemic sclerosis: a modification--relations to subtypes and the aminoterminal propeptide of type III procollagen (PIIINP).
Zachariae H; Bjerring P; Halkier-Sørensen L; Heickendorff L; Søndergaard K
Acta Derm Venereol; 1994 Nov; 74(6):444-6. PubMed ID: 7701875
[TBL] [Abstract][Full Text] [Related]
6. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. A follow-up--investigations in subclasses and during therapy.
Heickendorff L; Parvez A; Bjerring P; Halkier-Sørensen L; Zachariae H
Acta Derm Venereol; 1991; 71(3):185-8. PubMed ID: 1678217
[TBL] [Abstract][Full Text] [Related]
7. Carboxyterminal type I procollagen peptide concentrations in systemic sclerosis: higher levels in early diffuse disease.
Scheja A; Hellmer G; Wollheim FA; Akesson A
Br J Rheumatol; 1993 Jan; 32(1):59-62. PubMed ID: 8422562
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis.
Scheja A; Akesson A; Hørslev-Petersen K
Scand J Rheumatol; 1992; 21(1):5-9. PubMed ID: 1570489
[TBL] [Abstract][Full Text] [Related]
9. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.
Lee YJ; Shin KC; Kang SW; Lee EB; Kim HA; Song YW
Clin Exp Rheumatol; 2001; 19(1):69-74. PubMed ID: 11247328
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of type III collagen aminopropeptide in patients with systemic scleroderma.
Majewski S; Skiendzielewska A; Makieła B; Jablońska S; Błaszczyk M
Arch Dermatol Res; 1987; 279(7):484-6. PubMed ID: 3435177
[No Abstract] [Full Text] [Related]
11. Serum and urinary aminoterminal type III procollagen peptide in progressive systemic sclerosis: relationship to sclerodermal involvement, serum hyaluronan and urinary collagen metabolites.
Hørslev-Petersen K; Ammitzbøll T; Engström-Laurent A; Bentsen K; Junker P; Asboe-Hansen G; Lorenzen I
J Rheumatol; 1988 Mar; 15(3):460-7. PubMed ID: 3259985
[TBL] [Abstract][Full Text] [Related]
12. Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis.
Kikuchi K; Ihn H; Sato S; Igarashi A; Soma Y; Ishibashi Y; Takehara K
Arch Dermatol Res; 1994; 286(2):77-80. PubMed ID: 8154928
[TBL] [Abstract][Full Text] [Related]
13. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis.
Zachariae H; Aslam HM; Bjerring P; Søgaard H; Zachariae E; Heickendorff L
J Am Acad Dermatol; 1991 Jul; 25(1 Pt 1):50-3. PubMed ID: 1880254
[TBL] [Abstract][Full Text] [Related]
14. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma).
Scheja A; Akesson A; Geborek P; Wildt M; Wollheim CB; Wollheim FA; Vischer UM
Arthritis Res; 2001; 3(3):178-82. PubMed ID: 11299058
[TBL] [Abstract][Full Text] [Related]
15. Increased levels of type I and III collagen and hyaluronan in scleroderma skin.
Søndergaard K; Heickendorff L; Risteli L; Risteli J; Zachariae H; Stengaard-Pedersen K; Deleuran B
Br J Dermatol; 1997 Jan; 136(1):47-53. PubMed ID: 9039294
[TBL] [Abstract][Full Text] [Related]
16. Collagen metabolism in gynecologic patients: changes in the concentration of the aminoterminal propeptide of type III procollagen in serum.
Puistola U; Risteli L; Risteli J; Kauppila A
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1276-81. PubMed ID: 2220941
[TBL] [Abstract][Full Text] [Related]
17. Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen.
Oikarinen A; Autio P; Vuori J; Väänänen K; Risteli L; Kiistala U; Risteli J
Br J Dermatol; 1992 Feb; 126(2):172-8. PubMed ID: 1536783
[TBL] [Abstract][Full Text] [Related]
18. Bioactivity of prolactin in systemic sclerosis.
La Montagna G; Meli R; Criscuolo T; D'Angelo S; Valentini G
Clin Exp Rheumatol; 2004; 22(2):145-50. PubMed ID: 15083880
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of aminoterminal propeptide of type III procollagen and propeptide of human type I procollagen in systemic lupus erythematosus.
Villa-Manzano AI; Gamez-Nava JI; Salazar-Paramo M; Valera-Gonzalez IC; Garcia-Gonzalez A; Garcia-Gonzalez G; Morales-Romero J; Lopez-Olivo A; Galvan-Ramirez LM; Ruiz-Ruvalcaba R; Cardona-Muñoz EG; Gonzalez-Lopez L
Rheumatol Int; 2006 Jun; 26(8):712-6. PubMed ID: 16231121
[TBL] [Abstract][Full Text] [Related]
20. Primary fibromyalgia: clinical parameters in relation to serum procollagen type III aminoterminal peptide.
Jacobsen S; Jensen LT; Foldager M; Danneskiold-Samsøe B
Br J Rheumatol; 1990 Jun; 29(3):174-7. PubMed ID: 2357497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]